Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2019
Price : $35 *
At a glance
- Drugs Brimonidine (Primary)
- Indications Dry age-related macular degeneration
- Focus Therapeutic Use
- Acronyms BEACON
- Sponsors Allergan
- 29 Aug 2018 Status changed from active, no longer recruiting to discontinued.
- 13 Apr 2018 This trial was Completed in Germany (End date: 2018-03-30), according to European Clinical Trials Database.
- 23 Feb 2018 This trial was Discontinued in Italy, according to European Clinical Trials Database.